Satellite manufacturer York Space Systems (YSS.US) submits IPO application, aiming to raise $400 million.
York Space Systems (YSS.US), which manufactures satellites and critical mission systems for space and defense projects, submitted documents to the U.S. Securities and Exchange Commission on Monday, planning to conduct an initial public offering, with the fundraising target expected to be as high as $400 million.
York Space Systems (YSS.US), which manufactures satellites and key mission systems for space and defense projects, submitted documents to the U.S. Securities and Exchange Commission on Monday, planning to conduct an initial public offering with an expected fundraising size of up to $400 million.
York is a prime contractor in the space and defense sector, providing design, manufacturing, integration, and operational services for spacecraft platforms. Its spacecraft series includes the S-CLASS, LX-CLASS, and M-CLASS families. York is the top supplier for the U.S. Department of Defense's PWSA program, currently operating 33 spacecraft in orbit with 6 contracts of various types.
The company has completed 74 missions, with 17 legacy products that have accumulated over 4 million hours of on-orbit operation. The company operates over 45 ground antennas globally.
Founded in 2012 and headquartered in Denver, Colorado, the company reported revenue of $357 million for the 12 months ending September 30, 2025. The company plans to list on the New York Stock Exchange under the ticker symbol YSS. York Space Systems previously submitted a confidential application on September 29, 2025. The joint bookrunners for this offering are Goldman Sachs Group, Inc., Jefferies Financial Group Inc., and Wells Fargo & Company Securities. The company has not disclosed specific pricing terms yet.
Related Articles

Smart flying golden Thai(688443.SH): Celltrion's monoclonal antibody injection included in the 2025 National Medical Insurance Catalog.

HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.
Smart flying golden Thai(688443.SH): Celltrion's monoclonal antibody injection included in the 2025 National Medical Insurance Catalog.

HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.






